Back to List

Lunit Announces Financial Results for the First Half of 2022

Aug 19, 2022 — 5 min read

Lunit Media

  • Consolidated revenue in the second quarter of 2022 increased by 190% compared to same prior-year period

  • Total revenue for H1 2022 amounted to KRW 5.48 billion, or 82.5% of the total revenue of last year

[SEOUL, South Korea, Aug. 12, 2022] Lunit (KRX: 328130.KQ), a global provider of AI-powered cancer solutions, today announced strong financial results for the second quarter of the fiscal year 2022.

“Through a strong overseas performance in the first half of this year, Lunit achieved more than 80% of last year’s total sales within the first half of 2022,” said Brandon Suh, CEO of Lunit. “With more partnerships to come and the annual health examination season coming up in the third and fourth quarters, we expect our revenue to increase significantly during the second half of the year.”

Reporting under a consolidated basis, Lunit recorded a cumulative revenue of KRW 5.48 billion for the first half of 2022, reaching 82.5% of total sales for the previous year. H1 revenue for 2022 more than tripled compared to the same prior-year period (KRW 1.42 billion) and the proportion of overseas sales jumped from 66.8% to 84.3% year-over-year.

Lunit’s second quarter 2022 revenue was KRW 2.51 billion, up 190% from the prior-year period (KRW 863 million), among which overseas revenue accounted for 80.6%.

AIbiomarkerBreastBreast RadiographyCancerCorporateFujiFilmInvestmentIPOKOSDAQLunit INSIGHTLunit SCOPEMedicalMicrosoftMMGOncologyPartnershipPathologyRadiologyTechnologyTreatment

More from News